BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:Roche Diagnostics in healthcare: Opportunities\, Areas and Insight
 s from a Global Industry Player
DTSTART:20180828T140000
DTEND:20180828T144500
DTSTAMP:20260506T020322Z
UID:3024fee6de2a98e15cfdf68b8abf16a352b1871b2b41f127b2f82b2b
CATEGORIES:Conferences - Seminars
DESCRIPTION:Miro Venturi\, Roche Diagnostics\, Global Head Diagnostics Bio
 markers and Personalized Medicine\n\nCatalyze4Life (https://catalyze4life.
 epfl.ch/) is happy to announce the following seminar:\n \nTitle: “Roche
  Diagnostics in healthcare: opportunities\, focus areas and insights from 
 a global industry player"\n \nSpeaker: Dr. Miro Venturi - Global Head Dia
 gnostics Biomarkers & Personalized Medicine at Roche Diagnostics \n \nPl
 ace: SV1717 https://plan.epfl.ch/?room=SV1717\n\nTime: 28.08.2018 at 14:00
 \n \nBackground: In vitro diagnostics (IVDs) have long been considered th
 e “silent champion” of healthcare\, influencing over 60 % of clinical 
 decision-making\, while accounting for only about 2% of total healthcare s
 pending.\nRoche Diagnostics is the world leader in in vitro diagnostics an
 d tissue-based cancer diagnostics\, and a frontrunner in diabetes manageme
 nt.\nDiagnostics allows laboratories to be the reliable partners that heal
 thcare professionals need. It empowers doctors to make the right decisions
  for their patients at the right time\; it allows people to have improved 
 control over their health and wellbeing\; and it gives payers and policyma
 kers the confidence that they are investing in the right solutions for pat
 ients and the future of healthcare.\nModern diagnostics reduces costs by d
 iminishing subsequent health problems\, reducing hospitalisation and avoid
 ing unnecessary treatment. The future of sustainable healthcare depends on
  diagnostics.\nRoche diagnostics is constantly looking for innovative tech
 nologies to better serve patients. With this purpose in focus\, Catalyze4L
 ife is promoting exchanges between Life Science Researchers at EPFL and Ro
 che.\n \nMiro’s Biography\nAfter receiving his PhD from the Max-Planck 
 Institute of Biophysics in Frankfurt\, Miro specialized in molecular medic
 ine\, virology and immunology at the National Institutes of Health\, Bethe
 sda\, USA. In 2002\, Miro joined the pharmaceutical industry as a Biomarke
 r Laboratory Head and project team representative at Pharmacia Corp (later
  Pfizer Inc.) at the Oncology R&D site located in Nerviano\, Italy. In thi
 s role\, he initially established the biomarker laboratories and actively 
 contributed to the development of numerous oncology programs focusing on s
 mall molecular weight kinase inhibitors\, including the early development 
 of sunitinib (Sutent) as well as research and exploratory biomarker strate
 gies for several preclinical programs\, from lead optimization until PoC c
 linical studies. In 2005\, Miro was invited to join the faculty of the Uni
 versity “Vita Salute San Raffaele” in Milan as Adjunct Professor of pr
 eclinical and early clinical development of biopharmaceuticals. In 2007 Mi
 ro moved to Novartis as Divisional Head in Biomarker Development\, supervi
 sing a team of scientists developing assays and supporting project teams i
 n the realization of personalized medicine strategies across the portfolio
 \, with a focus on biologics and oncology programs. His team has contribut
 ed to the development of nilotinib (Tasigna) and early programs in both so
 lid tumors and hematological malignancies. Since 2009\, Miro joined Roche 
 Oncology where he has contributed the biomarker and personalized medicine 
 strategies and directed the execution for global drug development programs
  with companion diagnostics\, including the development and approval of Pe
 rjeta in breast cancer. In 2011\, he was appointed Site Head for Oncology 
 Biomarkers within the DTA Oncology Dept\, under the leadership of William 
 Pao\, and based in Penzberg\, Germany.\nMiro has then been appointed Globa
 l Head of Diagnostics Biomarkers at Hoffmann-la Roche and is based at the 
 Company´s headquarters in Basel. Miro has contributed to several drug res
 earch and scientific development projects and published in a number of rel
 evant scientific journals\, including Nature\, Cell\, PNAS and others.\n 
LOCATION:SV 1717 https://plan.epfl.ch/?room==SV%201717
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR